AEF0117

CAS No. 1610878-71-1

AEF0117( —— )

Catalog No. M37258 CAS No. 1610878-71-1

AEF0117, a signaling-specific inhibitor of cannabinoid receptor 1 (CB1-SSi), inhibits cannabinoid self-administration and behavioral disorders associated with THC, and can be used to study cannabis withdrawal.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 46 Get Quote
5MG 61 Get Quote
10MG 93 Get Quote
25MG 182 Get Quote
50MG 302 Get Quote
100MG 484 Get Quote
500MG 1035 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    AEF0117
  • Note
    Research use only, not for human use.
  • Brief Description
    AEF0117, a signaling-specific inhibitor of cannabinoid receptor 1 (CB1-SSi), inhibits cannabinoid self-administration and behavioral disorders associated with THC, and can be used to study cannabis withdrawal.
  • Description
    AEF0117 a signaling-specific inhibitor of the cannabinoid receptor 1 (CB1-SSi). AEF0117 plays an important role in Cannabis use disorder (CUD).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    GPCR/G Protein
  • Target
    Cannabinoid Receptor
  • Recptor
    Cannabinoid Receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1610878-71-1
  • Formula Weight
    436.63
  • Molecular Formula
    C29H40O3
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C[C@@]12[C@@]3([C@]([C@]4([C@](C)(CC3)[C@@H](C(C)=O)CC4)[H])(CC=C1C[C@@H](OCC5=CC=C(OC)C=C5)CC2)[H])[H]
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Margaret Haney, et al. Signaling-specific inhibition of the CB1 receptor for cannabis use disorder: phase 1 and phase 2a randomized trials. Nat Med. 2023 Jun;29(6):1487-1499.?
molnova catalog
related products
  • CP-724714

    CP-724714 is an effective and selective HER2/ErbB2 inhibitor (IC50: 10 nM), >640-fold selectivity against EGFR, Abl, InsR, PDGFR, IRG-1R, Src, VEGFR2, c-Met etc.

  • EHP-101

    VCE-004.8 is a specific dual agonist of PPARγ and CB2 receptor with potent anti-inflammatory activity. VCE-004.8 attenuates adipogenesis and prevents diet-induced obesity.

  • CB1R antagonist 1

    CB1R antagonist 1 is a potent CB1R antagonist that can be used to study diseases related to the nervous system.